Back to Search
Start Over
The maximum chemiluminescence intensity predicts severe neutropenia in gemcitabine-treated patients with pancreatic or biliary tract cancer.
- Source :
-
Cancer Chemotherapy & Pharmacology . Dec2018, Vol. 82 Issue 6, p953-960. 8p. - Publication Year :
- 2018
-
Abstract
- <bold>Purpose: </bold>To assess the predictive ability of the maximum chemiluminescence intensity (CImax) for severe neutropenia (SN) during neoadjuvant chemo(radio)therapy [NAC(RT)] in patients with advanced pancreatic or biliary tract cancer.<bold>Methods: </bold>Clinicopathological variables and blood test data before NAC(RT) were evaluated in 64 patients with advanced pancreatic or biliary tract cancer who received gemcitabine plus tegafur/gimeracil/oteracil as NAC(RT).<bold>Results: </bold>Thirty-nine patients (60.9%) developed Grade 3-4 SN. The median time between commencing NAC(RT) and the onset of SN was 15 (range 10-36) days. SN occurred during the NAC period, not the RT period. The CImax, neutrophil count, serum interleukin-6 level, C-reactive protein level, complement C3 titer, serum complement titer, and 50.0% hemolytic unit of complement before NAC(RT) were significantly lower in patients with SN than in those without SN (Pā<ā0.05). Multivariate analysis confirmed the CImax to be the sole independent predictor of SN (Pā<ā0.05). The optimal threshold for the CImax was 46,000 RLU/s. The sensitivity and specificity were 46.2% and 80.0%, respectively. Majority of the patients (81.8%) with a low CImax before NAC(RT) experienced SN during NAC(RT).<bold>Conclusions: </bold>CImax before NAC(RT) predicts SN during NAC(RT) in patients with advanced pancreatic or biliary tract cancer. [ABSTRACT FROM AUTHOR]
- Subjects :
- *CANCER chemotherapy
*NEUTROPENIA
*CHEMILUMINESCENCE
*BLOOD testing
*INTERLEUKIN-6
Subjects
Details
- Language :
- English
- ISSN :
- 03445704
- Volume :
- 82
- Issue :
- 6
- Database :
- Academic Search Index
- Journal :
- Cancer Chemotherapy & Pharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 133176059
- Full Text :
- https://doi.org/10.1007/s00280-018-3685-6